Sotorasib

N/A

Report date: 2025/10/14 17:23:47
NME

Base Information

Drug NameSotorasib
Drug Alias Nameソトラシブ索托雷塞LUMAKRASLUMYKRASAMG-510
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitors
TargetsKRAS G12C
Therapy Area/IndicationsSolid tumoursHepatic InsufficiencyCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/05/28
Country/TerritoryBelgiumCanadaUnited States +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Europe BvYonsei UniversityNational Cancer Institute +[8] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursHepatic InsufficiencyCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG